This form contains the information submitted by measure developers/stewards, organized according to NQF’s measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the [submitting standards web page](#).

<table>
<thead>
<tr>
<th>NQF #: 0746</th>
<th>NQF Project: Perinatal and Reproductive Health Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>(for Endorsement Maintenance Review)</td>
<td>Original Endorsement Date: Most Recent Endorsement Date:</td>
</tr>
</tbody>
</table>

## BRIEF MEASURE INFORMATION

**De.1 Measure Title:** In-hospital Neonatal Death  
**Co.1.1 Measure Steward:** Beth Israel Deaconess Medical Center

**De.2 Brief Description of Measure:** Any inborn with discharge disposition of died within 7 days of birth (perinatal death), excluding birth weight < 2500 grams, gestational age < 37 weeks, cases with congenital anomalies (DX codes 740-759.9), fetal hydrops (778.0), or dwarfism (259.4)

**2a1.1 Numerator Statement:** Any inborn with discharge disposition of died within 7 days of birth (perinatal death) who does not meet exclusion criteria

**2a1.4 Denominator Statement:** All inborns with birth weight >= 2500 grams and >= 37 gestational age and without exclusion criteria

**2a1.8 Denominator Exclusions:** None

**1.1 Measure Type:** Outcome  
**2a1. 25-26 Data Source:** Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record  
**2a1.33 Level of Analysis:** Clinician : Team, Facility

**1.2-1.4 Is this measure paired with another measure?** No

**De.3 If included in a composite, please identify the composite measure (title and NQF number if endorsed):**  
Adverse Outcome Index, Weighted Adverse Outcome Score and Severity Index

## STAFF NOTES (issues or questions regarding any criteria)

**Comments on Conditions for Consideration:**

Is the measure untested? Yes ☐ No ☐ If untested, explain how it meets criteria for consideration for time-limited endorsement:

1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (check De.5):

5. Similar/related [endorsed](#) or submitted measures (check 5.1):

Other Criteria:

**Staff Reviewer Name(s):**

## 1. IMPACT, OPPORTUITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See [guidance on evidence](#).  
**Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria.** (evaluation criteria)
1a. High Impact: 

[ ] H [ ] M [ ] L [ ] I [ ]

(The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.)

De.4 Subject/Topic Areas (Check all the areas that apply): Perinatal

De.5 Cross Cutting Areas (Check all the areas that apply): Care Coordination, Disparities, Safety, Safety : Complications

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, Patient/societal consequences of poor quality

1a.2 If “Other,” please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):

A delivery is one of the highest volume reasons for hospitalization; a potentially preventable neonatal death has overwhelming long term implications for the mother and family.

The infant mortality rate in the United States is nearly 7/1000 births. At term, this rates is approximately 2.5/1000 live births, with large racial and socio-economic variations. This equates to approximately 10,000 term newborn deaths per year in the United States


1b. Opportunity for Improvement: 

[ ] H [ ] M [ ] L [ ] I [ ]

(There is a demonstrated performance gap - variability or overall less than optimal performance)

1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:

While perinatal mortality rates have declined over time, it remains a significant complication, with devastating impact on the family. It has been estimated that up to 1/3 of neonatal deaths are preventable.

Access to Obstetric care and the quality of care provided have been associated with decreased neonatal and perinatal death rates.

1b.2 Summary of Data Demonstrating Performance Gap (Variation or overall less than optimal performance across providers):

[For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]

A large number of neonatal deaths are preventable, often with relatively simple measures. The Joint Commission found that 72% of perinatal events leading to neonatal deaths were associated with communication failure.

1b.3 Citations for Data on Performance Gap: [For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]


1b.4 Summary of Data on Disparities by Population Group: [For Maintenance – Descriptive statistics for performance results for this measure by population group]

It has been well demonstrated that ethnic differences and differences in access to health care are associated with differences in neonatal death rates.

1b.5 Citations for Data on Disparities Cited in 1b.4: [For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]


1c. Evidence (Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.)

Is the measure focus a health outcome? Yes No If not a health outcome, rate the body of evidence.

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Quality</th>
<th>Consistency</th>
<th>Does the measure pass subcriterion 1c?</th>
</tr>
</thead>
<tbody>
<tr>
<td>M-H</td>
<td>M-H</td>
<td>M-H</td>
<td>Yes</td>
</tr>
<tr>
<td>L</td>
<td>M-H</td>
<td>M</td>
<td>Yes IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No</td>
</tr>
<tr>
<td>M-H</td>
<td>L</td>
<td>M-H</td>
<td>Yes IF potential benefits to patients clearly outweigh potential harms: otherwise No</td>
</tr>
<tr>
<td>L-M-H</td>
<td>L-M-H</td>
<td>L</td>
<td>No</td>
</tr>
</tbody>
</table>

Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service

Does the measure pass subcriterion 1c?

Yes IF rationale supports relationship

1c.1 Structure-Process-Outcome Relationship (Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process-health outcome; intermediate clinical outcome-health outcome):

Health outcome; process-health outcome

Access to Obstetric care and the quality of care provided have been associated with decreased neonatal and perinatal death rates.

1c.2-3 Type of Evidence (Check all that apply):

Other, Selected individual studies (rather than entire body of evidence), Systematic review of body of evidence (other than within guideline development)

This measure is one of 10 adverse events that make up the Adverse Outcome Index (AOI). There are at least 10 studies that have used this composite as the primary outcome measure since its introduction in 2006. It has also, been used in numerous QI initiatives at the hospital level, system level and in state-wide collaboratives and was recently identified by the ACOG publication “Quality and Safety in Women’s Health Care” 2nd edition, 2010 as one of several quality monitoring tools currently available. We will site reports/articles from these initiatives.
1c.4 Directness of Evidence to the Specified Measure (State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population):


Neonatal death is a major component of the Adverse Outcomes Index (AOI).

The references below all used the AOI as a main outcome measure in a research setting:


OBJECTIVE: To evaluate the effect of teamwork training on the occurrence of adverse outcomes and process of care in labor and delivery.

METHODS: A cluster-randomized controlled trial was conducted at seven intervention and eight control hospitals. The intervention was a standardized teamwork training curriculum based on crew resource management that emphasized communication and team structure. The primary outcome was the proportion of deliveries at 20 weeks or more of gestation in which one or more adverse maternal or neonatal outcomes or both occurred (Adverse Outcome Index). Additional outcomes included 11 clinical process measures.

RESULTS: A total of 1,307 personnel were trained and 28,536 deliveries analyzed. At baseline, there were no differences in demographic or delivery characteristics between the groups. The mean Adverse Outcome Index prevalence was similar in the control and intervention groups, both at baseline and after implementation of teamwork training (9.4% versus 9.0% and 7.2% versus 8.3%, respectively). The intracluster correlation coefficient was 0.015, with a resultant wide confidence interval for the difference in mean Adverse Outcome Index between groups (–5.6% to 3.2%). One process measure, the time from the decision to perform an immediate cesarean delivery to the incision, differed significantly after team training (33.3 minutes versus 21.2 minutes, P=.03).

CONCLUSION: Training, as was conducted and implemented, did not transfer to a detectable impact in this study. The Adverse Outcome Index could be an important tool for comparing obstetric outcomes within and between institutions to help guide quality improvement.

The original randomized control study conducted by the Department of Defense (DoD) and Beth Israel Deaconess Medical Center (BIDMC) was an analysis of the impact of team training on adverse events occurring in L&D. The Adverse Outcome Index was developed by an expert panel including representatives from each participating hospital, ACOG, ASOAP, AF Institute of Pathology, US Navy BUMED, Office of Surgeon General and TRICARE. The expert panel identified the 10 adverse events and work with the ACOG Quality Committee to assign the weights. All of the original 10 events and assigned weights are included in the current AOI.


The authors, clinicians at Yale New Haven Hospital (YNHH) and their malpractice carrier, MCIC Vermont INC created a partnership from 2004-2006 to review and improve their patient safety climate. There were multiple interventions that included: review from outside experts, protocol standardization, implementing a patient safety nurse and patient safety committee, team training, and fetal heart monitoring training. The use of the AOI was used to track specific obstetrical adverse outcomes; the events were compiled on a monthly basis. YNHH was able to see a significant decrease in their AOI rate.

Other studies:


1c.5 Quantity of Studies in the Body of Evidence (Total number of studies, not articles): Hundreds of studies have been aimed at preventing neonatal death. These range from improving management of pregnancy to prevent premature delivery, to changes in labor management, to better care of the newborn once delivered.

1c.6 Quality of Body of Evidence (Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events): There is a wide range in quality of the body of evidence relating the quality of obstetric care to perinatal mortality. Prospective randomized trials and meta-analyses demonstrate that ante-natal corticosteroids improve neonatal outcomes (including death) in the preterm infant. In contrast, the impact of team training or simulation have been shown to prevent adverse neonatal outcomes only through population-based analysis.

In addition to those cited above the AOI has been used in collaboratives in Maryland, Greater NY Hospital Association, North Bronx
Healthcare Network, North Shore-LIJ Health System, a network of Premier hospitals and at many individual hospitals across the US. The AOI has been cited in at least 40 references.

The original DoD/BIDMC study relied on abstracted data and included a Baseline period of two months before team training (intervention) and 5 months post team training. The study found a significant change in only one process measure and while there was a decline in the AOI from the Baseline to Follow-up period, the change was not significant. The study concluded that the time frame to assess the true impact of team training may have been to brief; current experience with the AOI has shown that there is generally a 6-9 month period required to realize the full impact of team training and movement in the AOI. Using administrative data to calculate the AOI, allows hospitals to look at a longer baseline period (1-2 years) and begin follow-up monitoring when the entire team is fully trained and continue monitoring indefinitely.

The references cited above indicate that the AOI consistently tracks with quality improvement efforts across a broad range of practice environments.

In subsequent use of AOI in conjunction with QI/team training initiatives, the evidence for the measure to stimulate improved communication and teamwork, measure outcomes before and after an intervention and demonstrate reduction in adverse events has been strong.


In 2007, Wyoming Medical Center in partnership with Marsh adopted three quality improvement tools: AOI, WAOS, and the SI. The obstetrical data collected is used for benchmarking purposes within the hospital and the hospital’s Captive (17 other western hospitals insured by Marsh). The average score for the first two quarters of 2007 were: AOI- 5.7%, WAOS- 0.62, and SI- 11. They were compared to the benchmark scores: AOI- 9.2%, WAOS- 3.0, and SI- 25, and against the captive hospital scores.

CM Pettker, MD "Clinical: Patient Safety in Obstetrics." MedPedia : Safety can be tested by outcome measures by tracking events and comparing them to evidence-based practices. Some adverse outcomes have been suggested for tracking, which include: maternal death, fetal/neonatal death, fetal injury/truma, cord pH<700, shoulder dystocia, and hysterectomy. The most common outcome measure is the adverse outcome index…. Pettker noted that a safety effort with a majority of the above elements showed a decrease in adverse events on an OB unit. The mean quarterly AOI decreased by 40-60%, and the change in quarterly AOI showed a significant decrease over time.

Janakiraman, Vanitha, and Jeffrey Ecker. "Quality in Obstetric Care: Measuring What Matters." Obstetrics & Gynecology 116.3 (2010): 728-32. American College of Obstetricians and Gynecologists. Sept. 2010. The adverse Outcome Index is one quality measure that is attractive due to its ability to collect a wide range of obstetric outcomes. However, it requires widespread data collection, which may be difficult for some organizations to implement. The AOI’s scoring system may favor cesarean deliveries, driving up C-section rates. The nulliparous C-section rate is a compelling quality measure, but it does not take into account complications or outcomes. The only way to improve obstetrical quality is to measure it, and then work at refining the measures.

Pettker MD, Christian M., and Edmund F. Funai MD. “Managing Obstetric Risk: Is Your Labor and Delivery Team Ready?” Modern Medicine. 1 Feb. 2011. The authors, physicians and professors at Yale University School of Medicine and Yale-New haven Hospital, reported that insufficient communication between providers and patients was the main cause of 60-70% of investigated sentinel events in all areas of medicine, and for obstetrics that percent was even higher at 72%. 55% of cases studied had a culture that prevented effective teamwork and communication.

1c.7 Consistency of Results across Studies (Summarize the consistency of the magnitude and direction of the effect): Neonatal death is a major component of the Adverse Outcomes Index (AOI).

Use of the AOI has shown remarkable consistency with most facilities improving between Baseline and Follow-up. Beginning performance often shows notable variation and often the hospitals with the highest Baseline AOI will improve the most. Hospitals without strong leadership or experience a change in leadership often have difficulty moving their rates. A number of hospitals will
usually improve their rates by improving the accuracy of their coding or through changes in practice patterns (NICU admits). The studies/articles published using the AOI as a measure of quality have consistently demonstrated that the AOI is responsive to quality improvement efforts, and tracks with other quality measures.

1c.8 **Net Benefit** *(Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms)*: 
It is clear that neonatal mortality is a major public health issue that largely impacts poor and underserved communities. On an international scale, perhaps as many as 4,000,000 babies die each year. Many of these deaths are preventable.

Neonatal death is a major component of the Adverse Outcomes Index (AOI). Reducing the frequency of any of the adverse events is a net benefit and improvement in quality. Hospitals with high AOI rates due to documentation and/or coding issues rather than quality issues have the opportunity to easily correct their administrative data to more accurately reflect the quality of their care—an additional net benefit to the hospital under review. If the frequency of adverse events is correct, they will guide the hospital to focus their resources and process improvement activities on those events that are the most serious and/or have the highest volume. Measurement of the AOI over time demonstrates the impact of those improvements and comparison to an external comparative benchmark allows the hospital to see their improvement relative to the benchmark.

1c.9 **Grading of Strength/Quality of the Body of Evidence**. Has the body of evidence been graded? **No**

1c.10 **If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias**:

1c.11 **System Used for Grading the Body of Evidence**: **Other**

1c.12 **If other, identify and describe the grading scale with definitions**: Consensus panels were developed for the identification of measures to be included in the composite measure (AOI). This included vetting each of the individual measures. Peter E. Nielsen, MD; Marlene B. Goldman, ScD; Susan Mann, MD; David E. Shapiro, Ph.D.; Ronald G. Marcus, MB,BCh.; Stephen D. Pratt, MD; Penny Greenberg, RN; Munish Gupta, MD; Patricia McNamee, RN, MS; Mary Salisbury, RN, MS; David J. Birnbach, MD; Paul A. Gluck, MD; Mark D. Pearlman, MD; Heidi King, MS; David N. Tornburg, MD, MPH; Benjamin P. Sachs, MB, BS.; Lauren B À les, MD; Naval Medical Center Camp Pendleton; Ronald Burkman, MD, Baystate Medical Center; Cynthia Brumfield, MD University of Alabama at Birmingham; Peter Cherouny, MD, University of Vermont-Fletcher Allen Health Care; Jack Cooley, MD, National Naval Medical Center; Harold Fox, MD, Johns Hopkins Medical Center; Elizabeth Golladay, MD, Tripler Army Medical Center; Lynn Leventis, MD, Naval Medical Center San Diego; Robert Lorenz, MD, William Beaumont Hospital; William Lucky, MD, Baptist Hospital of Miami; Patrick Nugent, MD, South Shore Hospital; Spike Lipschitz, MD, South Shore Hospital; Chris Stolle, MD, Naval Medical Center of Portsmouth; Cosmas van DeVen, MD, University of Michigan Medical Center; Frank Witter, MD, Johns Hopkins Medical Center, Eileen Hemman, EdD. and Tom Bennedetti, MD, Suznne Walker, RN, MPH and Thomas Strandjord, MD from the University of Washington. In addition, representatives from the American Congress of Obstetrics and Gynecology, the American Society for Obstetric Anesthesia and Perinatology, the American Society of Anesthesiologists, the Association of Women’s Health, Obstetric and Neonatal Nurses, the Armed Forces Institute of Pathology, the U.S. Navy Bureau of Medicine and Surgery, the Office of the Surgeon General, U.S. Army and TRICARE were present.

1c.13 **Grade Assigned to the Body of Evidence**:

1c.14 **Summary of Controversy/Contradictory Evidence**: Prematurity remains a leading cause of the high infant rate in the United States. The proposed measure excludes these deaths.

1c.15 **Citations for Evidence other than Guidelines (Guidelines addressed below)**:

1c.16 **Quote verbatim, the specific guideline recommendation** *(Including guideline # and/or page #)*: No specific guidelines exist for the prevention of infant death. Guidelines for the prevention of some causes of infant death (e.g. fetal asphyxia) exist.

1c.17 **Clinical Practice Guideline Citation**: American College of Obstetricians and Gynecologists (ACOG). Intrapartum fetal heart

1c.18 National Guideline Clearinghouse or other URL:
http://www.guideline.gov/content.aspx?id=14885&search=fetal+heart+rate

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? Yes

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: ACOG

1c.21 System Used for Grading the Strength of Guideline Recommendation: USPSTF

1c.22 If other, identify and describe the grading scale with definitions:

1c.23 Grade Assigned to the Recommendation: A - C

1c.24 Rationale for Using this Guideline Over Others: Only Guideline relevant to this topic

Based on the NQF descriptions for rating the evidence, what was the developer’s assessment of the quantity, quality, and consistency of the body of evidence?

1c.25 Quantity: High
1c.26 Quality: Moderate
1c.27 Consistency: Moderate

Was the threshold criterion, Importance to Measure and Report, met? (1a & 1b must be rated moderate or high and 1c yes) Yes No

Provide rationale based on specific subcriteria:

For a new measure if the Committee votes NO, then STOP.
For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.

2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See guidance on measure testing.

S.1 Measure Web Page (In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained). Do you have a web page where current detailed specifications for this measure can be obtained? Yes

S.2 If yes, provide web page URL: www.npic.org (Sample AOI Report)

2a. RELIABILITY. Precise Specifications and Reliability Testing: H M L I

2a1. Precise Measure Specifications. (The measure specifications precise and unambiguous.)

2a1.1 Numerator Statement (Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome): Any inborn with discharge disposition of died within 7 days of birth (perinatal death) who does not meet exclusion criteria

2a1.2 Numerator Time Window (The time period in which the target process, condition, event, or outcome is eligible for inclusion): Within 7 days of delivery

2a1.3 Numerator Details (All information required to identify and calculate the cases from the target population with the target
NQF #0746 In-hospital Neonatal Death

process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses:
Admission source: born in this hospital, birth weight >= 2500 grams and Gestational Age >= 37 weeks and disposition = died; excluding cases with congenital anomalies (DX codes 740-759.9), fetal hydrops (778.0), or dwarfism (259.4).

2a1.4 Denominator Statement (Brief, narrative description of the target population being measured):
All inborns with birth weight >= 2500 grams and >= 37 gestational age and without exclusion criteria

2a1.5 Target Population Category (Check all the populations for which the measure is specified and tested if any): Children's Health

2a1.6 Denominator Time Window (The time period in which cases are eligible for inclusion):
Within 7 days of delivery (birth)

2a1.7 Denominator Details (All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):
For the AOI composite, all deliveries

2a1.8 Denominator Exclusions (Brief narrative description of exclusions from the target population):
None

2a1.9 Denominator Exclusion Details (All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):
None

2a1.10 Stratification Details/Variables (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):

2a1.11 Risk Adjustment Type (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): No risk adjustment or risk stratification 2a1.12 If "Other," please describe:

2a1.13 Statistical Risk Model and Variables (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):
NA except for exclusions

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

2a1.17-18. Type of Score: Rate/proportion

2a1.19 Interpretation of Score (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): Better quality = Lower score

2a1.20 Calculation Algorithm/Measure Logic (Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):
Inborns only; neonate >= 2500 grams and >= 37 weeks gestation with discharge disposition of died within 7 days of birth and excluding cases as above
NQF #0746 In-hospital Neonatal Death

<table>
<thead>
<tr>
<th>Component</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a1.21-23</td>
<td>Calculation Algorithm/Measure Logic Diagram URL or attachment:</td>
</tr>
</tbody>
</table>

| 2a1.24 | **Sampling (Survey) Methodology.** If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate): No sampling. |

| 2a1.25 | **Data Source** *(Check all the sources for which the measure is specified and tested).* If other, please describe: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record |

| 2a1.26 | **Data Source/Data Collection Instrument** *(Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.):* Administrative data set, UB04 |

| 2a1.27-29 | **Data Source/data Collection Instrument Reference Web Page URL or Attachment:** |

| 2a1.30-32 | **Data Dictionary/Code Table Web Page URL or Attachment:** |

| 2a1.33 | **Level of Analysis** *(Check the levels of analysis for which the measure is specified and tested):* Clinician : Team, Facility |

| 2a1.34-35 | **Care Setting** *(Check all the settings for which the measure is specified and tested):* Hospital/Acute Care Facility |

| 2a2. | **Reliability Testing.** *(Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)* |

| 2a2.1 | **Data/Sample** *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):* Administrative data for Beth Israel Deaconess Medical Center for the period Q 3, 2005- Q2 2006 was reconciled with abstracted data for the same period. In addition, all neonatal deaths from a cohort of eight hospitals that contract with NPIC and had validated data over a three year period were reviewed. |

| 2a2.2 | **Analytic Method** *(Describe method of reliability testing & rationale):* Case by case review. |

| 2a2.3 | **Testing Results** *(Reliability statistics, assessment of adequacy in the context of norms for the test conducted):* All neonatal deaths identified through manual abstraction of data were present on the administrative data set. |

| 2b. | **VALIDITY. Validity, Testing, including all Threats to Validity:** H□ M□ L□ I □ |

| 2b1.1 | **Describe how the measure specifications (measure focus, target population, and exclusions) are consistent with the evidence cited in support of the measure focus (criterion 1c) and identify any differences from the evidence:** Neonatal death is an objective measure and easily identified. Thus, our use is 100% consistent with the literature cited. |

| 2b2. | **Validity Testing.** *(Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.)* |

| 2b2.1 | **Data/Sample** *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):* Beth Israel Deaconess Medical Center has been tracking this adverse event as part of their Adverse Outcome Index since early 2001. Each case has been reviewed and validated against the extraction. |

| 2b2.2 | **Analytic Method** *(Describe method of validity testing and rationale; if face validity, describe systematic assessment):* Chart review and analysis of the administrative data set for all deliveries during the period. |
Tracking and measuring the rate of intraparutm neonatal deaths is critical to measuring the quality and safety of perinatal care.

### POTENTIAL THREATS TO VALIDITY

(All potential threats to validity were appropriately tested with adequate results.)

#### 2b3. Measure Exclusions

(Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.)

#### 2b3.1 Data/Sample for analysis of exclusions

(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

Beth Israel Deaconess Medical Center has been tracking this adverse event as part of their Adverse Outcome Index since early 2001. We perform ~5000 births per year. In addition, NPIC has tracked this outcome for nearly 150,000 births as part of the AOI project.

Data from nearly 28,000 births were tracked prospectively as part of a large randomized trial (Nielsen)

The original DoD/BIDMC study identified categories of patients where adverse events were not preventable and therefore need to be excluded from the AOI calculations. When the AOI was being translated into an algorithm to be used with administrative data, BIDMC cases identified using the algorithm were matched against cases identified during the study period and the differences reconciled.

#### 2b3.2 Analytic Method

(Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference):

Chart review of inborn deaths (with exclusions) using the AOI algorithm

Reconciling each case with an adverse event resulted in a fairly strong overlap between the administrative cases and abstracted study cases. There were some cases on the administrative list that were not on the abstracted case and vice versa. Each case was reviewed by analysts at BIDMC and NPIC/QAS resulting in refinement to the algorithm as well as improved identification of exclusions.

#### 2b3.3 Results

(Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):

The algorithm is highly sensitive, rarely is there a miscoding of the valid cases.

In the case by case review there was rarely significant variance in the total count of cases included in the original study count and identified using the administrative files indicating the exclusions were appropriately identified.

Some measure categories, especially those with very rare events (maternal/neonatal mortality, uterine rupture), pose a greater risk of missed exclusions or false inclusions. Providing total count of cases by review period and medical record numbers to hospitals under review, allow the hospital and team to correct the inaccuracies and use the AOI as a tool to accurately report and assess quality of labor and delivery care.

#### 2b4. Risk Adjustment Strategy

(For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.)

#### 2b4.1 Data/Sample

(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

NA

#### 2b4.2 Analytic Method

(Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables):

#### 2b4.3 Testing Results

(Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot,

---

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
NQF #0746 In-hospital Neonatal Death

and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata:

2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment: This is a weighted measure of the AOI composite measure. None of the individual measures with the AOI is risk adjusted although risk adjustment of the entire AOI is under consideration.

The AOI measure excludes cases that are not likely to be impacted by team training and are generally beyond the control of the clinician/team. The remaining cases are deemed to be able to be decreased regardless of the risk of the presenting patient. There are plans to look at risk adjustment in more detail but at this point the AOI is not risk adjusted.

2b5. Identification of Meaningful Differences in Performance. (The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.)

2b5.1 Data/Sample (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

This measure has been individually tracked as part of a composite measure (AOI). The AOI has been used in multiple published reports (see selected references below), totaling more than 50,000 deliveries. In addition, the National Perinatal Information center has tracked this across a wide range of clinical settings, totally nearly 300,000 deliveries.

There are two Collaboratives and approximately 30-40 individual hospitals that are using or have used the AOI in their QI programs, a total of ~ 100 hospitals (through NPIC/QAS). Total deliveries/inborns analyzed is greater than 300,000. Each hospital identified a Baseline period of 1-2 years, starting with discharges as early as 2006; for some hospitals the follow-up analysis is still on-going. Each hospital submits their administrative data set (UB 04) for all mothers and neonates 0-28 days old admission. The hospitals included all levels of care (OB Level I-III), teaching and non-teaching, urban and rural.


2b5.2 Analytic Method (Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):

This measure is part of the AOI composite measure. See AOI composite submission for details on measuring meaningful differences in performance.

Baseline and Follow-up calculations are made for the AOI, WAOS and SI for each hospital. The Baseline period is usually 4-8 quarters prior to an QI initiative- team training, simulation, NICHD common language, IHI bundle compliance training etc and a Follow-up period after the intervention. Percent change in each rate, test of statistically significant of trend and in comparison to a Baseline comparative rate and target benchmark are all calculated.

2b5.3 Results (Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):

Count of deaths tracked individually but rates calculated as overall AOI composite.

Summary data for 61 hospitals participating in a collaborative or team training program show the Baseline ranges for the AOI, WAOS and SI of .031-.130, .51-7.86 and 12.11-41.24 respectively. Follow-up ranges for the AOI were: .028-.088; for WAOS of .55-2.42 and the SI of 13.27-42.22.

For one collaborative of 16 hospitals, 5 improved on all 3 scores, 6 improved at least two scores. The overall rate of improvement for the AOI and WAOS was a decrease by 6.3% and .7 % respectively. The SI showed an increase of 2.7%.
The second collaborative of 20 hospitals had an average decrease for the AOI and WAOS of 2.08% and 1.8% respectively; the SI increased by 2.9%. 6 of the 20 showed improvement on all three scores; 5 improvement on 2 scores, 5 on 1 score and 4 declined.

### 2b6. Comparability of Multiple Data Sources/Methods

(If specified for more than one data source, the various approaches result in comparable scores.)

#### 2b6.1 Data/Sample

(Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included)

Hospitals using the composite measure -AOI- are continually testing the comparability of the counts of perinatal deaths found in the administrative data against chart abstracted data.

When the AOI was being translated into an algorithm to be used with administrative data, BIDMC cases identified using the algorithm were matched against cases identified during the study period and the differences reconciled.

Hospitals currently using the AOI receive numerator case lists so they reconcile their adverse event counts with chart review.

#### 2b6.2 Analytic Method

(Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure)

Medical record abstracting

Chart review validation or data from other sources (pharmacy, blood bank) shows a high degree of correlation with administrative data. We have used the administrative data algorithm exclusively since the original study allowing hospitals to submit supplemental data from other files when necessary. Other than in the first review with BIDMC we have not tested the comparability of scores using data exclusively from other sources.

#### 2b6.3 Testing Results

(Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted)

There were found no inaccuracies between the administrative data and chart abstracted data for this measure.

In the original review with BIDMC data, the overlap was very strong. Hospitals currently using the AOI, perform chart review comparisons regularly and find there is little discrepancy. As hospitals move toward a more integrated EHR, any discrepancy should be largely removed.

### 2c. Disparities in Care

(If applicable, the measure specifications allow identification of disparities.)

#### 2c.1 If measure is stratified for disparities, provide stratified results

(Scores by stratified categories/cohorts): Not stratified

#### 2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:

#### 2.1-2.3 Supplemental Testing Methodology Information:

Steering Committee: Overall, was the criterion, Scientific Acceptability of Measure Properties, met?

(Reactivity and Validity must be rated moderate or high) Yes[ ] No[ ]

Provide rationale based on specific subcriteria:

If the Committee votes No, STOP

### 3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

#### C.1 Intended Purpose/ Use

(Check all the purposes and/ or uses for which the measure is intended): Public Reporting, Quality
Improvement (Internal to the specific organization)

3.1 Current Use (Check all that apply; for any that are checked, provide the specific program information in the following questions): Public Reporting, Quality Improvement (Internal to the specific organization)

3a. Usefulness for Public Reporting:  H☐ M☐ L☐ I☐
(The measure is meaningful, understandable and useful for public reporting.)

3a.1. Use in Public Reporting - disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [For Maintenance – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]
Perinatal death rates are reported annually at state and national level.

3a.2. Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: Neonatal death is an objective event and thus easily understood. It is also a catastrophic outcome for the family involved.

3.2 Use for other Accountability Functions (payment, certification, accreditation). If used in a public accountability program, provide name of program(s), locations, Web page URL(s): This is widely used as a performance improvement measure at both the federal and state levels.

https://edocs.dhs.state.mn.us/fserver/Public/DHS-6263-ENG
http://aspe.hhs.gov/pic/perfimp/2001/hrsa.html#c10

3b. Usefulness for Quality Improvement:  H☐ M☐ L☐ I☐
(The measure is meaningful, understandable and useful for quality improvement.)

3b.1. Use in QI. If used in quality improvement program, provide name of program(s), locations, Web page URL(s): [For Maintenance – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].
As indicated in the importance section, both obstetric and neonatal management can have a significant impact on neonatal mortality rates. This includes appropriate pre-delivery and post-delivery management of the premature infant, appropriate care of the post-dates mother, improved performance during emergent events (shoulder dystocia, umbilical cord prolapse) and improved care of the high risk pregnancy (sever pre-eclampsia, fetal congenital anomalies), to name a few. Improvements in neonatal mortality could be achieved by improvements in any of these areas.

In addition, it has been used as part of the AOI in the following studies and collaboratives.


In 2007, Wyoming Medical Center I in partnership with Marsh adopted three quality improvement tools: AOI, WAOS, and the SI. The obstetrical data collected is used for benchmarking purposes within the hospital and the hospital's Captive (17 other western hospitals insured by Marsh). The average score for the first two quarters of 2007 were: AOI- 5.7%, WAOS- 0.62, and SI-11. They were compared to the benchmark scores: AOI- 9.2%, WAOS- 3.0, and SI- 25, and against the captive hospital scores.


3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results: See above

Overall, to what extent was the criterion, Usability, met? H M L I

Provide rationale based on specific subcriteria:

### 4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes: H M L I

4a.1-2 How are the data elements needed to compute measure scores generated? (Check all that apply).

Data used in the measure are:

- generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition,
- Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims)

4b. Electronic Sources: H M L I

4b.1 Are the data elements needed for the measure as specified available electronically (Elements that are needed to compute measure scores are in defined, computer-readable fields): Yes

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H M L I

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
### 4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:

**Inaccuracies are rare.**

Could be audited through chart review.

Audits during testing found no inaccuracies.

<table>
<thead>
<tr>
<th>4d. Data Collection Strategy/Implementation:</th>
<th>H</th>
<th>M</th>
<th>L</th>
<th>I</th>
</tr>
</thead>
</table>

### A.2 Please check if either of the following apply (regarding proprietary measures):

**4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):**

Using administrative/claims data presents few problem with regard to accurately identifying neonatal deaths. A discharge disposition of died and presence of a congenital anomaly or fetal hydrops are usually coded using ICD 9-CM codes. Birthweight is assumed to be >=2500 grams if the code 765.0 or 765.1 is not present on the record. The availability and cost effectiveness of using administrative data far outweighs manually abstracted data and does not sacrifice data accuracy.

### Overall, to what extent was the criterion, Feasibility, met?

**Provide rationale based on specific subcriteria:**

#### OVERALL SUITABILITY FOR ENDORSEMENT

**Does the measure meet all the NQF criteria for endorsement?**

Yes | No

**Rationale:**

If the Committee votes No, STOP.

If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.

#### 5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

**5.1 If there are related measures (either same measure focus or target population) or competing measures (both the same measure focus and same target population), list the NQF # and title of all related and/or competing measures:**

**5a. Harmonization**

**5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s):**

Are the measure specifications completely harmonized?

**5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:**

**5b. Competing Measure(s)**

**5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s):**

Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible):

#### CONTACT INFORMATION

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
Co.1 Measure Steward (Intellectual Property Owner): Beth Israel Deaconess Medical Center, 330 Brookline Ave, Dept. of OB/GYN; Dept of Anesthesia, Boston, Massachusetts, 02215

Co.2 Point of Contact: Janet, Muri, MBA, jmuri@npic.org, 401-274-0650-105

Co.3 Measure Developer if different from Measure Steward: Beth Israel Deaconess Medical Center, 330 Brookline Ave, Dept. of OB/GYN; Dept of Anesthesia, Boston, Massachusetts, 02215

Co.4 Point of Contact: Stephen, Pratt, MD, spratt@bidmc.harvard.edu, 617-667-3353-

Co.5 Submitter: Janet, Muri, MBA, jmuri@npic.org, 401-274-0650-105, National Perinatal Information Center

Co.6 Additional organizations that sponsored/participated in measure development:
Consensus panels were developed for the identification of measures to be included in the composite measure (AOI). This included vetting each of the individual measures.

Peter E. Nielsen, MD; Marlene B. Goldman, ScD; Susan Mann, MD; David E. Shapiro, Ph.D.; Ronald G. Marcus, MB, BCh.; Stephen D. Pratt, MD; Penny Greenberg, RN; Munish Gupta, MD; Patricia McNamee, RN, MS; Mary Salisbury, RN, MSN; David J. Birnbach, MD; Paul A. Gluck, MD; Mark D. Pearlman, MD; Heidi King, MS; David N. Tornburg, MD, MPH; Benjamin P. Sachs, MB, BS.; Lauren Bales, MD; Naval Medical Center Camp Pendleton; Ronald Burkman, MD, Baystate Medical Center; Cynthia Brumfield, MD University of Alabama at Birmingham; Peter Cherouny, MD, University of Vermont- Fletcher Allen Health Care; Jack Cooley, MD, National Naval Medical Center; Harold Fox, MD, Johns Hopkins Medical Center; Elizabeth Golladay, MD, Tripler Army Medical Center; Lynn Leventis, MD, Naval Medical Center San Diego; Robert Lorenz, MD, William Beaumont Hospital; William Lucky, MD, Baptist Hospital of Miami; Patrick Nugent, MD, South Shore Hospital; Spike Lipschitz, MD, South Shore Hospital; Chris Stolle, MD, Naval Medical Center of Portsmouth; Cosmas van DeVen, MD, University of Michigan Medical Center; Frank Witter, MD, Johns Hopkins Medical Center, Eileen Hemman, EdD. and Tom Bennedetti, MD, Suzanne Walker, RN, MPH and Thomas Strandjord, MD from the University of Washington. In addition, representatives from the American Congress of Obstetrics and Gynecology, the American Society for Obstetric Anesthesia and Perinatology, the American Society of Anesthesiologists, the Association of Women’s Health, Obstetric and Neonatal Nurses, the Armed Forces Institute of Pathology, the U.S. Navy Bureau of Medicine and Surgery, the Office of the Surgeon General, U.S. Army and TRICARE were present.

National Perinatal Information Center, Providence Rhode Island assisted with translating the AOI into administrative data specifications.

Co.7 Public Contact: Janet, Muri, MBA, jmuri@npic.org, 401-274-0650-105, National Perinatal Information Center

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development
Ad.1 Provide a list of sponsoring organizations and workgroup/panel members’ names and organizations. Describe the members’ role in measure development.

Consensus panels were developed for the identification of measures to be included in the composite measure (AOI). This included vetting each of the individual measures.

Peter E. Nielsen, MD; Marlene B. Goldman, ScD; Susan Mann, MD; David E. Shapiro, Ph.D.; Ronald G. Marcus, MB, BCh.; Stephen D. Pratt, MD; Penny Greenberg, RN; Munish Gupta, MD; Patricia McNamee, RN, MS; Mary Salisbury, RN, MSN; David J. Birnbach, MD; Paul A. Gluck, MD; Mark D. Pearlman, MD; Heidi King, MS; David N. Tornburg, MD, MPH; Benjamin P. Sachs, MB, BS.; Lauren Bales, MD; Naval Medical Center Camp Pendleton; Ronald Burkman, MD, Baystate Medical Center; Cynthia Brumfield, MD University of Alabama at Birmingham; Peter Cherouny, MD, University of Vermont- Fletcher Allen Health Care; Jack Cooley, MD, National Naval Medical Center; Harold Fox, MD, Johns Hopkins Medical Center; Elizabeth Golladay, MD, Tripler Army Medical Center; Lynn Leventis, MD, Naval Medical Center San Diego; Robert Lorenz, MD, William Beaumont Hospital; William Lucky, MD, Baptist Hospital of Miami; Patrick Nugent, MD, South Shore Hospital; Spike Lipschitz, MD, South Shore Hospital; Chris Stolle, MD, Naval Medical Center of Portsmouth; Cosmas van DeVen, MD, University of Michigan Medical Center; Frank Witter, MD, Johns Hopkins Medical Center, Eileen Hemman, EdD. and Tom Bennedetti, MD, Suzanne Walker, RN, MPH and Thomas Strandjord, MD from the University of Washington. In addition, representatives from the American Congress of Obstetrics and Gynecology, the American Society for Obstetric Anesthesia and Perinatology, the American Society of Anesthesiologists, the Association of Women’s Health, Obstetric and Neonatal Nurses, the Armed Forces Institute of Pathology, the U.S. Navy Bureau of Medicine and Surgery, the Office of the Surgeon General, U.S. Army and TRICARE were present.

National Perinatal Information Center, Providence Rhode Island assisted with translating the AOI into administrative data specifications.
**NQF #0746 In-hospital Neonatal Death**

| Medicine and Surgery, the Office of the Surgeon General, U.S. Army and TRICARE were present. |
| National Perinatal Information Center, Providence Rhode Island assisted with translating the AOI into administrative data specifications. |

| Ad.2 | If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward: |
| Measure Developer/Steward Updates and Ongoing Maintenance |
| Ad.3 | Year the measure was first released: 2007 |
| Ad.4 | Month and Year of most recent revision: 09, 2011 |
| Ad.5 | What is your frequency for review/update of this measure? Ongoing, last revision was 09/2011 |
| Ad.6 | When is the next scheduled review/update for this measure? 09, 2013 |

| Ad.7 | Copyright statement: |
| Ad.8 | Disclaimers: Recent revisions were made |
| Ad.9 | Additional Information/Comments: |

| Date of Submission (MM/DD/YY): 05/21/2010 |